Clinical Trials Directory

Trials / Completed

CompletedNCT02074319

RCT of Methotrexate Added to Treatment As Usual in Schizophrenia

A Randomised Double Blind Placebo Controlled 12 Week Trial of Methotrexate Added to Treatment As Usual in Early Schizophrenia

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
92 (actual)
Sponsor
Pakistan Institute of Living and Learning · Academic / Other
Sex
All
Age
18 Years – 35 Years
Healthy volunteers
Not accepted

Summary

The aim of the this study is to evaluate the effectiveness of methotrexate added to treatment as usual on positive and negative symptoms, cognitive and social functioning and quality of life of patients suffering from schizophrenia.

Detailed description

The purpose of the study is to test the prediction that addition of methotrexate to treatment as usual (TAU) for patients with schizophrenia will result in following outcomes: * Primary: * improvement in negative symptoms * improvement in positive symptoms * Secondary: * improvement in social functioning * improvement in cognitive functions * acceptability and tolerability of methotrexate added to TAU A total 72 participants (36 participants in intervention group and 36 in control group) meeting inclusion criteria of the study will be recruited and randomized in study in two arms. Research assistants and participating psychiatrists will assess participants for eligibility criteria. After providing detailed information regarding study by using patient information sheet, written informed consent will be taken from participants. Trained research assistant will asses participants at baseline, 2, 4, 6 and 12 weeks.

Conditions

Interventions

TypeNameDescription
DRUGMethotrexateTreatment as usual or standard treatment for psychosis will be common in all arms

Timeline

Start date
2013-12-01
Primary completion
2015-07-01
Completion
2015-08-01
First posted
2014-02-28
Last updated
2015-09-22

Locations

4 sites across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT02074319. Inclusion in this directory is not an endorsement.